Product Description
Product introduction
Darzalex 400mg Injection is used in the treatment of multiple myeloma, which is a type of cancer of plasma cells.
Darzalex 400mg Injection is given as an IV infusion into veins under the supervision of a doctor. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
Infusion reaction such as swollen face, lips, mouth, tongue or throat, difficulty swallowing or breathing are very common side effects. This medicine may reduce the number of blood cells (decrease white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells while taking this medicine.
Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. Use of effective contraception by both males and females during treatment is important to avoid pregnancy.
Mechanism of ActionDarzalex (daratumumab) is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells. By binding to CD38, the drug helps your immune system to recognize, attack, and destroy cancerous cells, providing a targeted and effective treatment for multiple myeloma patients.
Preparation and AdministrationThis medication requires dilution with appropriate intravenous fluids before administration. It is administered only via intravenous infusion in a controlled medical environment by a trained healthcare professional. The ready-to-use vial formulation ensures convenience while maintaining sterility and efficacy throughout its shelf life.
Safety and StorageDarzalex injection is latex-free and does not contain preservatives. Store the vials at 2C to 8C, avoiding freezing, and keep them protected from light to preserve effectiveness. Always check shelf life before use and dispose of any remaining solution after a single use to prevent contamination or reduced potency.
FAQ's of Darzalex Daratumumab 400 Mg Injection:
Q: How is Darzalex Daratumumab 400 mg Injection administered?
A: Darzalex is administered as an intravenous infusion and must be diluted prior to use. Administration should be performed by a healthcare professional in a clinical setting, following the prescribed schedule and dosage for each patient.
Q: What is the main indication for using Darzalex Daratumumab injection?
A: The primary indication for Darzalex Daratumumab 400 mg Injection is the treatment of multiple myeloma, a type of blood cancer affecting plasma cells. It is specifically prescribed for patients requiring targeted monoclonal antibody therapy.
Q: When should Darzalex Daratumumab be used, and who prescribes it?
A: Darzalex should be used according to the schedule and dosage prescribed by your oncologist or hematologist. It is available by prescription only (Rx), ensuring its use under the guidance and supervision of a qualified healthcare provider.
Q: Where should Darzalex Daratumumab vials be stored before use?
A: Store unopened vials in a refrigerator at 2C to 8C (36F to 46F), protected from light. Do not freeze the vials, and ensure proper storage to maintain the medication's efficacy and safety until use.
Q: What is the process for preparing Darzalex Daratumumab for infusion?
A: Before administration, Darzalex must be diluted with a suitable diluent as directed by medical guidelines. Once diluted, it is infused intravenously over a specified period by trained medical personnel to ensure safe and effective delivery.
Q: What are the benefits of using Darzalex Daratumumab in multiple myeloma treatment?
A: Darzalex offers a targeted approach by precisely attacking myeloma cells, potentially improving treatment responses and extending periods of disease control for patients with multiple myeloma. Its ready-to-use, preservative-free formulation also enhances safety during administration.
Q: Is Darzalex Daratumumab packaging latex-free and preservative-free?
A: Yes, Darzalex Daratumumab injection is supplied in latex-free vials and contains no preservatives, reducing the risk of allergic reactions and ensuring suitability for individuals with latex sensitivities.